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Matrix metalloproteinases (MMPs) degrade the extra-
cellular matrix and carry out key functions in cell
development, cancer, injury, and regeneration. In
addition to its well recognized extracellular action,
functional intracellular MMP activity under certain
conditions is supported by increasing evidence. In
this study, we observed higher gelatinase activity by
in situ zymography and increased MMP-9 immunore-
activity in human neuroblastoma cells and in bone
marrow macrophages undergoing mitosis compared
with resting cells. We studied the pattern of immuno-
reactivity at the different stages of cell division by
confocal microscopy. Immunostaining with different
monoclonal antibodies against MMP-9 revealed a pre-
cise, dynamic, and well orchestrated localization of
MMP-9 at the different stages of cell division. The
cellular distribution of MMP-9 staining was studied in
relation to that of microtubules. The spatial pattern of
MMP-9 immunoreactivity suggested some participa-
tion in both the reorganization of the nuclear content
and the process of chromatid segmentation. We then
used several MMP-9 inhibitors to find out whether
MMP-9 might be involved in the cell cycle. These
drugs impaired the entry of cells into mitosis, as
revealed by flow cytometry, and reduced cell culture
growth. In addition, the silencing of MMP-9 expres-
sion with small interfering RNA also reduced cell
growth. Taken together, these results suggest that in-
tracellular MMP-9 is involved in the process of cell
division in neuroblastoma cells and in primary cul-
tures of macrophages. (Am J Pathol 2010, 177:2870–2885;
DOI: 10.2353/ajpath.2010.090050)
Matrix metalloproteinases (MMPs) are zinc-dependent
endopeptidases that degrade several components of the
extracellular matrix. MMPs are normally found as latent
zymogens that become active through proteolytic cleav-
age1 by mechanisms ensuring sensitive and complex
regulation of MMP activity in vivo.2 The matrix undergoes
intense remodeling during development, neoplasia, in-
flammation, and tissue injury and recovery, which often
involves enhanced release of certain proteases. MMPs
are thought to have key functions in various pathological
conditions, such as diseases of the central nervous sys-
tem3 and cancer.4 Indeed, invasiveness requires that
tumoral cells degrade the basement membrane, and this
is associated with release of MMPs.4 In accordance,
MMP inhibitors attenuate tumor cell growth and/or inva-
sive capacity.5,6 For instance, MMP inhibitors with a
broad inhibitory spectrum suppress cervical lymph node
metastasis.7 Furthermore, increased MMP-9 expression
is associated with enhanced proliferative capacity in
mouse aortic smooth muscle cells,8 and mice injected
with lymphoma cells constitutively expressing MMP-9 de-
velop thymic lymphoma more rapidly than mice injected
with control lymphoma cells.9
Growth factors up-regulate certain MMPs, such as ge-
latinases MMP-2 and MMP-9, in gliomas.10 MMPs are
downstream targets of the epidermal growth factor re-
ceptor (EGFR) signaling pathway.11 Indeed, exposure of
breast or carcinoma cells to EGFR ligands increases cell
proliferation and induction of MMP-9,12–14 which is medi-
ated by mitogen-activated protein kinases.15 In addition,
the EGFR signaling pathway is associated with the pro-
teolytic and invasive phenotype in head and neck squa-
mous cell carcinomas.16 Transforming growth factor-
(TGF-) is a ligand for EGFR with mitogenic activity for
epithelial and mesenchymal cells.17,18 TGF- enhances
MMP-9 in cervical-carcinoma SKG-IIIb cells.19
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Although MMPs exert multiple functions in the extra-
cellular space, several lines of evidence support the pos-
sibility that MMPs could also play roles in functions inside
the cells.20,21 In this study we examined the intracellular
expression and activation of MMP-9 in neuroblastoma
cells and in primary cultures of rat macrophages, the
effects of MMP-9 inhibitors or of silencing MMP-9 expres-
sion in cell cycle and/or cell growth, and the response to
growth stimulation with TGF-. The results suggest that
MMP-9 is involved in certain steps of cell division in
neuroblastoma cells and in macrophages.
Materials and Methods
Neuroblastoma Cell Cultures and Drug
Treatments
Human neuroblastoma SH-SY5Y cells (European Collec-
tion of Cell Cultures, Salisbury, Wiltshire, UK) were grown
in Ham’s F12 and Eagle’s minimal essential medium (1:1)
containing 15% fetal calf serum, 1% nonessential amino
acids, 2 mmol/L glutamine, and 20 g/ml gentamicin at
37°C and 5% CO2 in a humidified atmosphere. N-Myc
amplified human neuroblastoma SK-N-BE-2C cells were
kindly provided by Dr. Jaume Mora (Hospital de Sant Joan
de Deu, Barcelona, Spain). All culture media and reagents
were from Invitrogen (GIBCO, Invitrogen SA, Barcelona,
Spain). Cells were seeded at the density of 3 to 4  103
cells/cm2, and drug treatment was initiated on the next day.
The MMP-9 inhibitors, inhibitor A (MMP-2/MMP-9 Inhib-
itor II 444249) and inhibitor B (MMP-9/MMP-13 Inhibitor I
444252), and the broad MMP inhibitor GM6001 were
obtained from Calbiochem (Darmstadt, Germany). Stock
solutions were prepared in dimethyl sulfoxide (0.5% in the
final concentration), and concentration-response curves
were studied. In each experiment, control cells (0 mol/L
inhibitor) were exposed to the vehicle for the same time.
Human recombinant TGF- (Calbiochem) was dissolved in
10 mmol/L acetic acid and then PBS to yield a neutral pH.
The day after seeding cells were exposed to TGF- (10
ng/ml), and studies were performed at different time points
ranging from 1 to 6 days. In some experiments the tyrosine
kinase activity of EGFR was inhibited with 10 mol/L 4,5-
dianilinophthalimide (RBI, Ko¨ln, Germany).
Primary Cultures of Rat Macrophages and
Treatments
Rat macrophages were obtained from the rat bone mar-
row, and primary cultures were prepared as described
previously.22 Adult Sprague-Dawley rats (320–350 g
b.wt.) were obtained from Charles River Laboratories
(Lyon, France). Rats were killed by decapitation, and
both femurs were dissected. Animal work was performed
in agreement with our local regulations and in compli-
ance with the Directives of the European Community. The
end of the bones was cut off, and the marrow tissue was
elicited by irrigation with culture medium (Dulbecco’s mod-
ified Eagle’s medium, Lonza/Bio-Whittaker, Basel, Switzer-
land). Cells were resuspended by vigorous pipetting and
washed once with Dulbecco’s modified Eagle’s medium.
Then cells were seeded into Petri dishes of 150-mm diam-
eter at a density of 107 cells per dish. A homogeneous
population of macrophages was obtained after 6 days in
culture. Cells were grown with medium supplemented with
10% fetal bovine serum and 30% of L-cell conditioned
medium. In an attempt to increase the rate of cell division,
macrophages were starved of L-cell conditioned medium
for 18 hours (L0) and, after this period, the medium was
added again for 6 hours (L1), 15 hours (L2), 20 hours (L3),
23 hours (L4), or 24 hours (L5).
Silencing MMP-9 Expression
Expression of MMP-9 was silenced with a small interfer-
ing RNA (siRNA) sequence against rat MMP-9 (ON-TAR-
GETplus SMARTpool siRNA sequences, Dharmacon,
Thermo Fisher Scientific, Cultek SL, Madrid, Spain). A
nontargeting siRNA (D-001810-01, Dharmacon) was
used as a negative control (ns-siRNA). siRNAs were
transfected into macrophages by electroporation, as re-
ported previously.22 In brief, the cells were collected and
washed twice with Dulbecco’s modified Eagle’s medium
and then resuspended at a final concentration of 107
cells/ml. Macrophages (400 l) were mixed with 1 mol/L
siRNA in 4-mm gap cuvettes (Bio-Rad Laboratories, Her-
cules, CA) and placed on ice for 20 minutes. Electropo-
ration was performed at 100 F, 300 V, 13  (27 ms)
with an electroporator (Bio-Rad Laboratories). Then the
samples were placed on ice for 10 minutes before recon-
stitution in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum and 30% of L-cell
conditioned medium. Subsequent assays were per-
formed 24 hours after transfection.
SK-N-BE-2C cells were transfected with human MMP-9
siRNA using Lipofectamine 2000 (Invitrogen) as the ve-
hicle, according to the manufacturer’s protocol. For the
transfection of SH-SY5Y cells we used electroporation
because we did not achieve a good silencing effect with
lipid carriers. The following siRNA duplex sequence was
used for human MMP-9 knockdown: GCGGAGAUUGG-
GAACCAGCUGUAUU (Stealth RNAi, MMP9HSS106625,
Invitrogen, Barcelona, Spain). A nontargeting RNAi was
used as a control (Stealth RNAi Negative Control Duplex,
12935-400, Invitrogen). In brief, 2 days after seeding, the
transfection was performed in OPTIMEM-minimal essen-
tial medium (Invitrogen) with a final siRNA concentration
of 120 nmol/L. The knockdown efficiencies of RNAi were
confirmed 3 days later by determining the decreases in
the level of human MMP-9 expression by RT-PCR using
the primers, Hmmp9() GCTCACCTTCACTCGCGTG
and Hmmp9() CGCGACACCAAACTGGATG, and the
control primers for human18S ribosomal RNA, H18s()
GCGAAAGCATTTGCCAAGAA and H18s() CATCACA-
GACCTGTTATTGC. After 2 and 3 days of treatment, cell
growth was evaluated with the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and the
ratio between the two MTT values was calculated to
assess cell growth per 24 hours under the different ex-
perimental conditions.
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Immunocytochemistry
For studies of immunocytochemistry, cells were cultured
in eight-well plastic chamber slides (NUNC, Roskilde,
Denmark). Cells were fixed with cold methanol for 10
minutes, washed three times with PBS, and incubated for
1 hour with the blocking solution containing 15% normal
goat or donkey serum. The primary antibodies were three
different monoclonal antibodies against MMP-9 (mouse
antibodies MAB13421, diluted 1:50 from Chemicon In-
ternational, Pacisa-Giralt, Barcelona, Spain; and AB-
10, diluted 1:50, from Oncogene, and rabbit antibody
ab76003, diluted 1:500, from Abcam, Inc., Cambridge,
MA), and a mouse monoclonal antibody against -tubulin
(diluted 1:50, Boehringer Mannheim, Germany). Incuba-
tion was performed overnight at 4°C in the presence of
1% normal goat or donkey serum, followed by either a red
fluorescent cyanine (Cy3)-labeled anti-mouse secondary
antibody made in donkey (Jackson ImmunoResearch
Laboratories, West Grove, PA), diluted 1:200, or a green
fluorescent fluorescein isothiocyanate (FITC)-labeled
secondary anti-mouse or anti-rabbit antibody (Molecular
Probes, Leiden, The Netherlands), diluted 1:1000, or a
red fluorescent Tetramethylrhodamine isothiocyanate
(TRITC)-labeled secondary anti-rabbit antibody (Sigma-Al-
drich, Alcobendas, Madrid, Spain) diluted 1:200. The sec-
ondary antibody was incubated for 1 hour at room tem-
perature in the presence of 1% normal donkey or goat
serum. After this, cells were washed with PBS, mounted
with a mounting media (Mowiol, Calbiochem, San Diego,
CA), and fluorescence was examined under a 40 ob-
jective in an optical microscope (Eclipse E1000M/E1000,
Nikon, IZASA, Barcelona, Spain) equipped with a super
high-pressure mercury lamp power supply (HB-10103AF,
Nikon). Red fluorescence from Cy3 fluorochrome (550 nm
excitation and 570 nm emision) and green FITC fluores-
cence (495 nm excitation and 519 nm emission) were ob-
served using the corresponding filter cubes G-2A and B-2A
(Nikon), respectively. Double staining was examined with
the confocal microscope (TCS-NT, Leica, Wetzlar, Ger-
many) under a 63 objective (PL APO 63/1.40 oil). The
confocal microscope was equipped with an argon-krypton
laser and was used at 568 nm (DD488/568) excitation with
a LP590 emission filter for red light, and at 510 nm (RSP510)
excitation with a BP530/30 emission filter for green light.
To visualize DNA, cells were counterstained with 5
g/ml bisbenzimide (Hoechst 33258 dye, Sigma-Aldrich)
in PBS for 20 minutes, which binds DNA and produces
UV light. Hoechst 33258 (359 nm excitation and 461 nm
emission) staining was examined under the fluorescence
microscope (Eclipse E1000M/E1000) with the corre-
sponding filter cube (UV-2A) using the 20 and 40
objectives. Triple color staining (Cy3, FITC, and UV) was
examined with a 63 magnification objective (HCX PL
APO 63/1.32 oil PH3 CS) in a confocal microscope
(SP2, Leica) equipped with UV excitation (argon laser-UV
351/364 nm), and the lasers used for green and red lights
were argon (488 nm) and helium-neon (543 nm), respec-
tively. Images were acquired with the corresponding
Leica confocal software. Figures composed of several
images were prepared with Adobe Photoshop software.
In a few experiments, we tested MMP-9 immunoreactivity
in cultured mouse fibroblasts kindly provided by Dr. Joan
Serratosa.
Flow Cytometry Analyses
The cell cycle was studied by measuring DNA cell con-
tent after incubation of fresh cells with 0.1% Triton X-100,
0.2 mg/ml RNase, and 25 g/ml propidium iodide (PI) for
30 minutes. Flow cytometry was performed with an Epics
XL flow cytometer (Coulter Corporation, Hialeah, FL). The
instrument was set up with the standard configuration:
excitation of the sample was done using a standard 488
nm air-cooled argon ion laser at 15 mW power. Forward
scatter, side scatter, red (620 nm) fluorescence for PI
was acquired. Red fluorescence was collected with a 645
dichroic long filter and a 675 band pass filter. Optical
alignment was based on optimized signal from 10-nm
fluorescent beads (Immunocheck, Epics Division,
Aberystwyth, Wales, UK). Time was used as a control of
the stability of the instrument. Red fluorescence was pro-
jected on a 1024 monoparametrical histogram and DNA
analysis (ploidy analysis) was done using Multicycle soft-
ware (Phoenix Flow Systems, San Diego, CA). Aggre-
gates were excluded, gating single cells by their area
versus peak fluorescence signal.
MMP-9 content along the cell cycle was analyzed
by antibody staining. Cells were harvested by mild
trypsinization (0.01% trypsin in PBS with 0.02% EDTA),
washed with PBS, and resuspended in 0.5 ml of PBS.
Methanol at 20°C was added drop to drop up to a
volume of 5 ml. After 4 hours of fixation, cells were per-
meabilized with 2.5% Triton X-100 for 5 minutes, prein-
cubated with 1% bovine serum albumin in PBS, and
incubated overnight at 4°C with a mouse monoclonal
antibody against MMP-9 (MAB 13421, diluted 1:50,
Chemicon International, Temecula, CA) in a roller shaking
in the presence of 1% BSA. Cells were washed twice with
PBS and incubated with the secondary antibody FITC
conjugated (1:100) for 1 hour. Cells were counterstained
with PI as detailed above, and flow cytometry was per-
formed. Green (525 nmol/L) fluorescence for FITC-con-
jugated antibody was collected with a 550 dichroic long
filter and a 525 band pass filter. Quantification of MMP-9
stain (FITC) intensity at distinct phases of the cell cycle
(PI staining) was done simultaneously on FITC/immuno-
precipitation dot plots.
Assays of Cell Growth and Cytotoxicity
Changes in cell growth were determined by the reduction
of the tetrazolium salt MTT (Sigma-Aldrich) to the colored
product formazan, a general measure of cellular oxida-
tive capacity. MTT was dissolved at a concentration of 5
mg/ml in PBS, sterilized by filtration, and stored for up to
1 month at 4°C protected from light and tightly capped.
This mixture was added to the 96-well cell culture plates
at a final concentration of 0.5 mg/ml, and the plates were
returned to an incubator. Two hours later, incubation was
terminated by adding extraction solution (100 l/well)
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containing 20% SDS in N,N-dimethyl formamide/water
(1:1), pH 4.7. The plates were tightly wrapped with
Parafilm to avoid evaporation and incubated overnight at
37°C. Optical density was measured at 570 nm (refer-
ence wavelength 630 nm), using the extraction buffer
solution as a blank, in a plate reader (iEMS Reader MF,
Labsystems, Helsinki, Findland).
Cell number counting was determined in parallel ex-
periments using the trypan blue dye exclusion assay to
check the viability of the cells. Cultures in 12-well plates
were washed with PBS and mildly trypsinized in the pres-
ence of 0.02% EDTA. The reaction was stopped by add-
ing 5% fetal bovine serum, and the cells were washed
and resuspended in 0.5 ml of PBS. One-half milliliter of
0.4% trypan blue solution (w/v) was added to each sam-
ple, mixed, and allowed to stand for 5 to 15 minutes.
Viable (nonstained) and nonviable (stained) cells were
counted in a hemocytometer.
The presence of mitosis was studied in 24-well plates
after nuclear staining with Hoechst 33258 dye. Staining
was observed under an inverted microscope (IX50/IX70,
Olympus, Tokyo, Japan) equipped with an inverted re-
flected light fluorescence observation attachment (IX-
FLA) containing a mercury lamp and appropriate filter
cube (U-MWU, BP 330 to 385 nm excitation) and barrier
filter (BA420) for UV light. Mitotic figures were counted
and were related to the number of cells in each micro-
scopic field using the 20 objective.
PI staining was used to identify the presence of dead
cells in fresh (nonfixed) cultures. PI enters cells with
damaged membranes and greatly increases their fluo-
rescence by binding to nucleic acids. PI was added to
the cultures at a final concentration of 15 g/ml and was
incubated for 30 minutes, and then media with PI was
washed with warm PBS and the cultures were immediately
observed under the inverted microscope (IX50/IX70, Olym-
pus), as above, using an appropriate filter cube (U-MNG,
BP 530 to 550 nm excitation) and barrier filter (BA590).
Gelatinase Extraction and Gel Zymography
Culture medium was separated from the cells, which
were trypsinized and washed with PBS, and the cellular
pellets were subjected to detergent extraction and puri-
fication of gelatinolytic activity following the method de-
scribed by Zhang and Gottschall,23 with modifications as
reported.24–26 In brief, samples were homogenized in
lysis buffer (250 l per 2 to 4 100-mm dishes) containing
detergents (Brij-35 and 1% Triton X-100). All reagents,
unless otherwise stated, were from Sigma-Aldrich. Ho-
mogenates were centrifuged at 12,000  g for 5 minutes,
and an aliquot of the supernatant was taken as the pro-
tein fraction for Western blot analysis. The rest of the
supernatant was incubated with gelatin-Sepharose 4B
(25 l, Amersham Biosciences Europe GmbH, Frigurg,
Germany) for 1 hour at 4°C. After washing, MMPs were
separated from the Sepharose pellet by incubation with
30 l of elution buffer containing 10% dimethyl sulfoxide
for 30 minutes at 4°C. Gel zymography was performed
with samples of extracted cells (equivalent to 50 g of
protein in the supernatant after homogenization). Gels
containing 10% acrylamide and porcine gelatin (1 mg/ml)
were prepared, and electrophoresis followed by gel
staining was performed, as reported.23 A mixture of
MMP-9 and MMP-2 containing gelatinase (CC073,
Chemicon International) was used as a standard.
MMP activity was inhibited by using either the broad-
spectrum MMP inhibitor GM6001 (10 mol/L) or EDTA
(10 mmol/L) that was applied to the incubation medium of
the zymography gels after electrophoresis. The inhibitor
was prepared in dimethyl sulfoxide at a concentration of
10 mmol/L and then diluted in the incubation buffer to the
working concentration.
Real-Time RT-PCR
Expression of MMP-9 mRNA in cultured macrophages
was studied by Real-Time RT-PCR. For cDNA synthesis,
1 g of RNA was subjected to transcription using Molo-
ney murine leukemia virus reverse transcriptase RNase H
minus point mutant, oligo(dt)15 primer and PCR nucleo-
tide mix (Promega, Madison MT). Then real time-PCR
was performed using a kit (Bio-Rad Laboratories). The
final volume was 15 l of SYBR Green Master Mix. The
primers were GTATTGGAAGTTCTCGAATCAC for MMP-9
() and CAAGTCGAATTTCCAGATACG for MMP-9 ().
Quantification was performed with rat hypoxanthine gua-
nine phosphoribosyl transferase 1 (HPRT1) gene as the
reference, using the following primers: CTGAAGAGCTACT-
GTAATGACCA for HPRT1 () and CCTGTATCCAACACT-
TCGAG for HPRT1 ().
Western Blotting
Samples from the protein fraction were subjected to
Western blot analysis, as reported previously,24 with
monoclonal antibodies against MMP-9 (mouse monoclo-
nal antibody, diluted 1:150, MAB13420 from Chemicon
International; and a rabbit monoclonal antibody, diluted
1:5000, ab76003 from Abcam). A mouse monoclonal
antibody against -tubulin (Boehringer Mannheim, Mann-
heim, Germany), diluted 1:5000, was used to control
protein gel loading. Secondary antibody was peroxidase-
linked anti-mouse Ig (Amersham, Madrid, Spain), diluted
1:2000. The reaction was developed with a chemilumi-
nescence method. Gels were scanned with a Kodak
camera (DC-120) and analyzed with appropriate soft-
ware to determine band intensity (Kds1D, Eastman
Kodak, Rochester, NY).
In Situ Gelatin Zymography
Cells were cultured in eight-well plastic slides and incu-
bated with 10 g/ml FITC-labeled DQ-gelatin (Molecular
Probes, Eugene, OR) for 1 hour at room temperature in a
humidified chamber. Then sections were washed with
PBS and counterstained with Hoechst 33258 dye. Green
FITC fluorescence indicative of gelatinase activity was
observed under a 20 objective of the fluorescence
microscope (Eclipse E1000M/E1000) with the corre-
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sponding filter cube (B-2A), as stated above for immu-
nostaining. The same fields were observed under the UV
light to visualize DNA staining with Hoechst 33258 dye
using the appropriate filter cube (UV-2A, Nikon). In situ
zymography was performed in the presence or absence
of the broad spectrum MMP inhibitor 1,10-phenanthroline
monohydrate (0.2 mmol/L).
Treatment with Recombinant MMP-9
Macrophages and SK-N-BE-2C cells were treated with 50
or 100 ng/ml recombinant human MMP-9 (rMMP-9)
(ab39308, Abcam). Because serum contains MMP-9, this
experiment was performed after gelatinases were re-
moved from the serum by incubation overnight at 4°C
with gelatin-Sepharose 4B beads (diluted 1:10, Amer-
sham Biosciences Europe GmbH) that was previously
washed twice to remove ethanol. After incubation, beads
were removed from the sample by centrifugation for 5
minutes at 1000  g. The successful extraction of MMP-9
from serum was verified by Western blotting. The medium
of the cells was changed to medium containing either
normal serum or gelatinase-free serum, in the presence
or absence of added rMMP-9. Before the latter incuba-
tion, macrophages were deprived of L-cells for 16 hours
to stimulate cell growth at addition of the new medium
containing L-cells and the various serum conditions de-
scribed above. One day after exposure of macrophages
and neuroblastoma cells to normal serum or gelatinase-
free serum (containing or not containing additional rMMP-
9), cell growth was assessed with the MTT assay.
Statistical Analyses
Two groups were compared with Student’s t-test after
testing for normality. Multiple group comparisons were
performed by one-way analysis of variance followed by
Dunnett’s multiple comparison test or Bonferroni test
comparisons between the two groups. Nonlinear regres-
sion analysis was performed using GraphPad Prism soft-
ware. Goodness of fit was assessed by R2. Linear regres-
sion analysis was performed using the same software.
Results
MMP-9 in Mitotic Cells
The cellular distribution of MMP-9 immunoreactivity and
gelatinase activity was studied in SH-SY5Y cells (Figure
1, A–K). Faint MMP-9 staining was found in the cytoplasm
and cell extensions (Figure 1B), and very intense staining
Figure 1. High expression of MMP-9 immuno-
reactivity in cells undergoing cell division. A:
Phase-contrast image of SH-SY5Y neuroblas-
toma cells using the optical microscope. B:
MMP-9 immunofluorescent staining with a
mouse monoclonal antibody (Chemicon Inter-
national). Arrowheads point to strongly MMP-
9-immunoreactive cells (green). C: Cells under-
going mitosis as revealed with Hoechst 33258
dye (blue), which stains the dividing condensed
chromosomes (arrowheads) bright blue. D–F:
MMP-9 immunostaining (D, red, arrowheads)
and Hoechst 33258 staining (E, blue), showing
in the merged image (F) that MMP-9 immunore-
activity (red) surrounds the DNA (bright blue), in
cells at metaphase (arrowheads). G–I: MMP-9
staining (G, red, arrowheads) and correspond-
ing Hoechst 33258-stained mitotic cells (H,
bright blue, arrowheads) at metaphase (bot-
tom left) and anaphase (top right), again show-
ing correspondence in the merged image (I). J:
In situ gelatin zymography after incubation of
cultured cells with fluorescein-labeled gelatin
(see Materials and Methods). K: Green fluores-
cent staining reveals stronger gelatinase activity
in cells undergoing division (arrowheads), as
revealed with Hoechst 33258 dye (bright blue,
arrowheads). Strong gelatinase activity is seen
within mitotic cells in the area surrounding the
chromosomes. Scale bars A–C  50 m; D–K 
25 m.
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was found in cells undergoing mitosis (arrows in Figure
1). This was confirmed with double staining with bisben-
zimide (Hoechst 33258 dye), which binds DNA and pro-
duces UV light showing brighter staining in the con-
densed DNA of dividing cells (arrows in Figure 1C). In
mitotic cells (Figure 1, D–I), MMP-9 staining was distrib-
uted within the cell, excluding the area of the chromo-
somes. The specificity of the immunoreaction was tested
by using two different monoclonal antibodies against
MMP-9 (see Materials and Methods) with two different
fluorescent secondary anti-mouse antibodies (one la-
beled in green with FITC-fluorochrome [Figure 1B] and
the other labeled in red with Cy3-fluorochrome [Figure 1,
D and G]) and by omitting the primary antibody but not
the secondary fluorescent antibody, which gave no
signal.
To validate these findings, MMP-9 immunostaining was
performed with a mouse monoclonal antibody against
MMP-9 followed by a FITC-labeled anti-mouse secondary
antibody, combined with propidium iodide staining, and
the cells were analyzed by flow cytometry. FITC immu-
nofluorescence of cells in the S, G2, or M phases was
5.11  0.05 fluorescence units, a value that was higher (t
test P  0.0005, n  4) than that of cells at the G1 phase
(3.82  0.18 fluorescence units). These results showed
that MMP-9 staining was enhanced in cells undergoing
division.
In situ gelatin zymography using fluorescein-labeled
gelatin showed some low gelatinase activity in the cells
and a notably stronger activity in mitotic cells (Figure 1J),
as revealed with double staining with Hoechst 33258 dye
(Figure 1K). Gelatinase activity in mitotic cells was de-
tected within the cell body excluding the chromosomal
area (Figure 1, J and K).
Dynamic Distribution of MMP-9 Immunostaining
in Relation to Microtubules during Mitosis
MMP-9 immunoreactivity was very strong at prophase
(Figure 2A). To examine the cellular distribution of MMP-9
staining in relation to that of microtubules, we performed
double staining against MMP-9 and -tubulin (Figure 2).
MMP-9 immunoreactivity was detected surrounding the
mitotic spindle at the different stages of mitosis. At pro-
metaphase the nuclear envelope fenestrates, allowing
the microtubules entering the nucleus and forming the
mitotic spindle (see spring-like lattice structure labeled in
green in the cell at the top of Figure 2C). A thick wall of
MMP-9 immunostaining was distributed beyond the spin-
dle though prometaphase and metaphase (Figure 2C). At
early anaphase, when partition of the two sister chroma-
tids is initiated and before the two centrioles also begin to
separate toward opposite sides of the cell, the confocal
microscopy projection image (Figure 2D) showed MMP-9
immunostaining mainly distributed between the two poles
of the mitotic spindle. More detailed examination of dif-
ferent 0.5-m sections of the cell with confocal micros-
copy (Figure 2, E–I) showed MMP-9 staining in a central
location between the two poles of the spindle. During
cytokinesis (Figure 2J), by which segmentation takes
place, a ring of MMP-9 surrounded two clearly separated
zones containing one centriole each, which were inter-
connected through the microtubules of the spindle. At
this period, the segmentation sulk (arrow in Figure 2J) is
formed, allowing cytoplasm division and further separa-
tion of the two daughter cells. Omission of the primary
antibody against MMP-9 but in the presence of the sec-
ondary Cy3-labeled antibody, followed by reaction with
the primary anti--tubulin antibody and then the FITC-
labeled secondary antibody, produced no red reaction,
as only green staining showing -tubulin immunoreactiv-
ity became apparent (Figure 2B). These results indicate
that MMP-9 might be involved in the rearrangement of the
nuclear matrix, cell structures, and/or cytoplasm to allow
cell division once DNA was duplicated in neuroblastoma.
In addition, we examined whether this particular distribu-
tion of MMP-9 immunoreactivity detected in SH-SY5Y
cells was also observed in a different cell type. We per-
formed MMP-9 immunocytochemical analysis in mouse
fibroblasts and observed a higher intensity of staining in
mitotic cells (Figure 2L).
Images to better illustrate the presence of MMP-9 im-
munoreactivity during the process of cell division are
shown in Figures 3 and 4, where MMP-9 staining (red) is
combined with -tubulin staining (green) and Hoechst
staining (blue). Neuroblastoma cells showed MMP-9 im-
munoreactivity surrounding the DNA during the early
phases of mitosis from prophase to metaphase, before
the two sister chromatids begin to separate (Figures 3,
A–C and D–F, and 4, A–D). However, MMP-9 immunore-
activity became apparent in the center of the cell at the
time that the two chromatids began to separate at an-
aphase (Figures 3, G–I, and 4, E–L). At telophase, when
the two sets of chromosomes reach the poles of the
spindle and become completely partitioned (Figure 3,
J–L), MMP-9 immunoreactivity was located within the
segmentation sulk surrounding the contractile microtu-
bule ring. Then, at cytokinesis immunoreactivity sur-
rounded the daughter cells (Figure 3, M–O).
We also examined MMP-9 immunoreactivity in the N-
Myc-amplified neuroblastoma cell line, SK-N-BE-2C and
found a pattern of MMP-9 expression in mitotic cells
similar to that in SH-SY5Y cells (Supplemental Figure 1,
see http://ajp.amjpathol.org).
MMP-9 Inhibitors Caused Cell Cycle Alterations
The cell cycle was examined by flow cytometry using
propidium iodide staining after incubation of the cells for
1 or 3 days in the presence or absence of MMP inhibitors.
Inhibitor A is specific for MMP-9 and MMP-2, whereas
inhibitor B was designed to target MMP-9 and MMP-13.
Overall the inhibitors increased the percentage of cells in
the S phase, whereas they reduced the percentage of
cells in the G1 phase (Figure 5) (n  4 to 9 samples from
at least two independent experiments). For inhibitor A
(Figure 5A), the most marked effects were detected at
day 1. At this time, the percentage of cells in the S phase
significantly (one-way analysis of variance) increased in
relation to controls by 19% (P  0.05) and 38% (P 
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0.001) at the doses of 15 and 20 mol/L, respectively.
Significant reductions in the percentage of cells in the G1
phase were detected related to controls, i.e., 10% (P 
0.05) and 17% (P  0.001) at the doses of 15 and 20
mol/L, respectively. For inhibitor B (Figure 5B), the most
marked effects were seen at day 3 when an increase of
approximately 20% (P 0.001) in the percentage of cells
in the S phase was detected at the doses of 10 and 15
mol/L, together with an increase of approximately 16%
(P  0.05 at the dose of 10 mol/L) in the percentage of
cells in the G2 phase. This inhibitor significantly reduced
the percentage of cells in the G1 phase by approximately
5% (P  0.001). Examples of cycle analysis data are
shown in Figure 5C for a control and in Figure 5D for a cell
culture treated with MMP inhibitor A. These results indi-
cate that the MMP inhibitors reduced the ability of cells to
divide after DNA was synthesized during the S phase,
and cell proliferation was subsequently impaired.
MMP Inhibitors Reduced Cell Growth
We seeded the cells, let them grow for 2 days, and then
incubated the cultures (time 0) in the presence or ab-
sence of different inhibitor concentrations (5 to 30 mol/L
inhibitor A and 1 to 35 mol/L inhibitor B). Gel zymogra-
phy with cellular extracts showed the presence of intrin-
sic gelatinases in SH-SY5Y cells (Figure 6A). In control
cells, a faint MMP-9 band was observed together with a
more intense band corresponding to MMP-2. MMP inhib-
itor A targeting MMP-9 and MMP-2 reduced both gelati-
nase bands, whereas inhibitor B mainly affected MMP-9
(Figure 6B). Gelatinase bands were no longer seen when
zymography gels were exposed to EDTA in the incuba-
tion buffer because they require Ca2 (not shown).
The cell growth and viability MTT assay was performed
3 days after incubation in the presence or absence of the
inhibitors. The inhibitors significantly prevented cell
Figure 2. MMP-9 immunoreactivity and the mi-
totic spindle labeled with -tubulin. Confocal
microscope images showing MMP-9 immunore-
activity (red in A–K and green in L) and/or
-tubulin (green in A–K). The monoclonal anti-
body against MMP-9 was either from Oncogene
(A) or Chemicon International (B–L). Cells in
A–K are SH-SY5Y neuroblastoma cells, whereas
cells in L are mouse fibroblasts. A: Single immu-
nocytochemistry against MMP-9 shows strong
MMP-9 immunostaining in a cell at prophase. B:
Negative control for double immunocytochem-
istry against MMP-9 and -tubulin, in which the
primary antibody against MMP-9 was omitted.
Arrows show the two poles of the mitotic spin-
dle in a dividing cell. C: Cells at prophase (top)
and metaphase (bottom) showing MMP-9 (red,
arrows) located behind the centrosomes (green,
arrowheads). D–I: Cell at anaphase showing
MMP-9 (red, arrow) between the two poles
(arrowheads) of the mitotic spindle (green). D:
Projection image. E–I: Sequential 0.5-m sec-
tions through the cell. J: Cell at cytokinesis
showing the two separated daughter cells sur-
rounded by MMP-9 immunoreactivity and con-
nected by the rest of the spindle microtubules at
the segmentation sulk (arrow). K: Cell at pro-
metaphase (asterisk) and cell at cytokinesis
showing two clearly distinguished MMP-9-im-
munostained areas (red, arrows) surrounding
the two daughter cells, which are connected
through the microtubules of the spindle (arrow-
head). L: MMP-9 staining (green) is stronger in
dividing (arrows) than in resting fibroblasts.
Arrows (C–K) point to zones of MMP-9-immu-
noreactivity, and arrowheads point to the tu-
bulin-positive mitotic spindle in dividing cells.
Arrows in L point to MMP-9-positive cells. Scale
bar  15 m.
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growth in a concentration-dependent manner as the MTT
values were progressively reduced in relation to the con-
trol (Figure 6, C and D). Data were fit to two-phase expo-
nential decay equations (R2  0.86 for inhibitor A; R2 
0.87 for inhibitor B).
We performed the MTT assay at time 0 and at day 3
after incubation in the presence or absence of the inhib-
itors and determined the MTT values at day 3 as the
percent increase in relation to MTT at time 0 (basal) to
assess whether inhibitors reduced MTT to values below
basal. In control cell cultures (vehicle-treated in the ab-
sence of inhibitors), the MTT values increased by 75%
from time 0 to day 3. Exposure to concentrations of
inhibitors up to 20 mol/L for 3 days reduced (P 0.001)
the MTT value in relation to that for the controls without
affecting cell viability (Figure 7, A and B). However, the
highest doses (from 20 mol/L) reduced (P 0.001) MTT
to values lower than basal MTT at time 0, thus suggesting
that prolonged exposure to the highest concentrations of
inhibitors might have some toxic effects in neuroblastoma
cells. The numbers of living and dead cells in the cultures
were counted by means of the trypan blue dye exclusion
Figure 3. MMP-9 immunoreactivity through the
different mitotic stages. Staining with antibodies
against MMP-9 (Chemicon International) (red)
and -tubulin (green) and Hoechst DNA staining
(blue). A–E: Cells at different phases of mitosis.
The first picture of each row (left) shows the
maximal projection confocal image, whereas the
two pictures on the right of each row correspond
to 0.5-m-thick sections of the same cell, respec-
tively. A–C and D–F: Cells at metaphase (m),
showing DNA condensation (blue, arrowhead)
and centrosomes (green), as labeled with -tu-
bulin, are surrounded by intense red staining
against MMP-9 (arrow). G–I: Two mitotic cells,
one at metaphase (m) (bottom left) and one at
anaphase (a) (top right). The cell at anaphase,
characterized by a greater separation between
the poles of the spindle and chromatid partition
(arrowheads), show MMP-9 staining (arrow)
that is located surrounding the DNA and also
between the separating chromatids. J–L: Cell at
telophase (t), which exhibits a completed chro-
matid partition (arrowheads) through the con-
tractile ring, shows MMP-9 staining (arrows)
between the two chromatids. M–O: Two daugh-
ter cells at cytokinesis (c), which are still con-
nected through the rest of the mitotic spindle or
medial corps (green), show MMP-9 staining (ar-
rows) surrounding the chromatids (arrow-
heads). Arrows point to MMP-9 staining and
arrowheads point to DNA. Scale bar  15 m.
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assay to assess cell death. The number of dead cells
(expressed as the percentage of total cell number) was
not increased by 3-day exposure to inhibitors (15 and 20
mol/L for inhibitor A and 10 and 15 mol/L for inhibitor
B) compared with that in the 3-day vehicle-treated control
(Figure 7C). However, the number of living cells was
reduced (P  0.001) by approximately 30% after the
3-day exposure to 20 mol/L inhibitor A or 15 mol/L
inhibitor B (Figure 7D), despite the fact that cell death
was not promoted by these treatments. These results
strongly suggest that the inhibitors reduced cell growth at
concentrations that caused no toxicity to the cells. This
finding was validated in another set of experiments in
which cultures were examined using the optical micro-
scope and the fluorescence microscope after PI staining,
because no signs of induced cell death were observed
(not shown).
We then incubated the cultures with the inhibitors for 2
days instead of 3 days and performed the MTT assay to
determine whether a similar effect on cell growth could
be observed with shorter exposure times. At 2 days, cell
growth was reduced (20%, P  0.001) by 30 mol/L
inhibitor A (Supplemental Figure 2A, see http://ajp.
amjpathol.org) and 36 mol/L inhibitor B (Supplemental
Figure 2B, see http://ajp.amjpathol.org). Compared with
this 2-day exposure, the concentrations needed to cause
20% MTT reduction with the 3-day exposure were ap-
proximately 15 mol/L inhibitor A and 10 mol/L inhibitor
B, and therefore the effect of the inhibitors on cell growth
was time-dependent. We also checked that the 2-day
exposure did not cause cell death by performing the
trypan blue exclusion assay after inhibitor incubation,
which showed that cell death was not enhanced by
the treatment (Supplemental Figure 2C, see http://ajp.
amjpathol.org). Indeed, the mean  SEM percentage of
dead cells (in relation to total number of cells) was 7.4 
2.53% in controls at time 0 and 13.1  0.96% in controls
at time 2-days, whereas the corresponding value after
2-day exposure to 30 mol/L inhibitor A was 5.2  0%.
Again, the trypan blue exclusion assay showed that the
number of cells increased by 3.6-fold from 0 to 2 days
under control conditions, whereas under exposure to the
inhibitor the increase was limited to 1.3-fold (Supplemen-
tal Figure 2D, see http://ajp.amjpathol.org). In addition, we
Figure 4. Confocal microscopy images showing
details of the subcellular location of MMP-9 im-
munoreactivity at certain mitotic phases. Stain-
ing with antibodies against MMP-9 (Chemicon
International) (red) and -tubulin (green) and
Hoechst DNA staining (blue). A: Projection con-
focal image of a cell at prophase (p) surrounded
by MMP-9-like immunoreactivity (arrow). B:
Section (0.5-m-thick) of the cell shown in A.
The zone of microtubule (green) depolymeriza-
tion for centrosome formation is in close prox-
imity to MMP-9 immunoreactivity (red), as is
shown by the yellow area in the center of the
cell. C: Projection confocal image of a cell at late
prophase-prometaphase (p-m), showing a thick
wall of intense MMP-9 staining (arrow) sur-
rounding the DNA (blue). D: Section (0.5-m-
thick) of the cell shown in C, showing the cen-
trosome and forming a mitotic spindle (light
blue) on the top of DNA (dark blue). E and I:
Images of cells at anaphase (an) (merged image)
are composed of corresponding single images of
-tubulin (F and J, green), MMP-9 immunoreac-
tivity (G and K, red), and DNA (H and L, blue).
E: Cell at anaphase showing that MMP-9 staining
is in close proximity to the microtubules (yel-
low). F: Enlargement of the kinetocore microtu-
bules located between the separating chroma-
tids as marked in H with an arrowhead. At this
stage, MMP-9 staining (arrow in G) is apparent
between the separating chromatids (H). I: Cell at
anaphase showing increased separation be-
tween the poles of the spindle, with acquisition
of a fusiform shape and with MMP-9 staining at
the migrating opposite poles of the cells. J
shows microtubules and K shows MMP-9 stain-
ing (arrow) between the two separating chro-
matids (shown in L, arrowhead). Arrows point
to MMP-9 staining and arrowheads point to
DNA. Scale bar  10 m.
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examined the cells using the fluorescence microscope
after propidium iodide staining, and no signs of in-
creased cell death were observed (not shown).
To validate these findings, we silenced MMP-9 expres-
sion with siRNA in SH-SY5Y cells. After silencing of
MMP-9, the expression of MMP-9 mRNA was reduced by
36% versus treatment with nonsilencing RNA (nsRNA),
and the expression of the protein was also attenuated
(Supplemental Figure 2E, see http://ajp.amjpathol.org).
These changes paralleled a concomitant 15% reduction
(P  0.001) in cell growth at day 4 after transfection with
siRNA-MMP-9 versus nsRNA (Figure 7E).
We then investigated whether MMP-9 was involved in
cell division in the N-Myc-amplified neuroblastoma cell
line, SK-N-BE-2C, by silencing MMP-9 expression with
siRNA. We achieved a mean reduction in MMP-9 mRNA
expression of 44%, as assessed by real-time RT-PCR,
and a corresponding 37% reduction in MMP-9 protein
expression versus nsRNA as assessed by Western blot-
ting (Supplemental Figure 2F, see http://ajp.amj-
pathol.org). This effect also caused a small (15%), but
significant (P  0.01), reduction of cell growth compared
with that of cells receiving nonsilencing RNA.
Action of a Growth Factor and Effect of MMP
Inhibitors
Treatment with 10 ng/ml TGF- for 6 days (Figure 8, A
and B) increased cell growth and proliferation as re-
vealed by the MTT assay (Figure 8C) and by cell counting
(Figure 8D), and more mitotic figures were seen after
DNA staining with Hoechst 33258 dye (2.0  0.08%
mitotic cells) compared with those in controls at the same
Figure 5. MMP-9 inhibitors disturb the cell cy-
cle. A: After 1 day of incubation in the presence
or absence of inhibitor A, cells were labeled with
propidium iodide, and the cell cycle was exam-
ined by flow cytometry. The percentage of cells
in the S phase increases (P  0.05 and P  0.01
at the doses of 15 and 20 mol/L, respectively)
with the inhibitors in relation to the vehicle-
treated control. The inhibitor also significantly
reduces the percentage of cells in the G1 phase
(P  0.05 and P  0.01 at the doses of 15 and 20
mol/L, respectively). B: Likewise, the percent-
ages of cells in the S phase (P  0.001) and G2
phase (P  0.05) increase, whereas that of cells
in the G1 phase decreased (P  0.001) after a
3-day exposure to inhibitor B at doses of 10 and
15 mol/L. Data are expressed as the mean 
SEM (n  6 to 4) percentage of cells in each
cycle phase. Results were analyzed by one-way
analysis of variance followed by Dunnett’s mul-
tiple comparison test to evaluate the effects of
treatments against the control. Representative
examples of the flow cytometry analysis are
shown in C and D for a control and for 20
mol/L inhibitor A, respectively.
Figure 6. MMP inhibitors reduce cell growth in
a concentration-dependent manner. A: Gel zy-
mography shows reduction of gelatinase activity
after incubation the cells for 3 days in the pres-
ence of the inhibitors. B: Inhibitor A reduces
MMP-9 and MMP-2 activity, whereas inhibitor B
has a greater effect on MMP-9 than on MMP-2
activity. C and D: Concentration-response curves
for which the response is evaluated with the
MTT assay as an assessment of cell culture
growth. Cultures were exposed to the inhibitor
for 3 days. C: Effect of inhibitor A with concen-
trations ranging from 0 to 30 mol/L. D: Effect of
inhibitor B with concentrations ranging from 0 to
35 mol/L. Curves are fit with nonlinear regres-
sion to two-phase exponential decay equations
using GraphPad Prism software. R2  0.86 and
0.87 for inhibitor A and B, respectively. Each
data point is expressed as the percentage of the
mean MTT value obtained in the control (3-day
vehicle-treated with inhibitor concentration 0) and
is the mean SD of n 6 to 18 values obtained in
two to three independent experiments.
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time point (1.4 0.10%mitotic cells). TGF--induced cell
growth was dependent on the activity of the EGFR, as
inhibition of the receptor tyrosine kinase activity with 10
mol/L 4,5-dianilinophthalimide reduced cell growth (P
0.001) and returned growth rate to control values (Figure
9E). Exposure of cultures treated with TGF- to MMP
inhibitors for 2 days significantly reduced MTT values in a
dose-dependent manner (Figure 8, F and G), suggesting
that MMP activity supports neuroblastoma culture cell
growth under a variety of conditions bearing different cell
growth rates.
Western blotting showed the prozymogen form of MMP-9
as a 94-kDa band together with a fainter band of lower
molecular mass (approximately 88 kDa) that was associ-
ated with proteolytic cleavage of the proform (Figure 8A).
TGF- enhanced cleavage of the proform and expression
of the lower molecular mass form (Figure 8H). Zymography
assays of cellular gelatinase extracts (Figure 8I) revealed
that TGF- enhanced gelatin degradation and appearance
of a band of approximately 88 kDa, thus corresponding to
an active MMP-9 form. These results suggest that MMP-9 is
further activated in neuroblastoma cells with a higher
growth rate after TGF--treatment.
MMP-9 Expression in Primary Cultures of
Macrophages
To test whether the above findings in neuroblastoma cells
were also seen in other cells, we examined primary cul-
tures of macrophages obtained from rat bone marrow.
Macrophages were stained with MMP-9 antibodies and
again higher cellular MMP-9 expression was detected in
dividing cells (Figure 9, A–F). To verify antibody specific-
ity we preabsorbed the antibody with human recombi-
nant MMP-9 and found lower intensity of staining under
these conditions (Supplemental Figure 3, see http://ajp.
amjpathol.org). In addition, in situ zymography showed
increased gelatinase activity in dividing cells (Figure 9G),
whereas gelatinase activity was lost in the presence of a
broad-spectrum MMP inhibitor (1,10-phenanthroline mo-
nohydrate) (Figure 9H). These findings suggest that MMP
expression and activity are increased in macrophages
undergoing mitosis.
In an attempt to increase the numbers of dividing
macrophages, we starved the cells from L-cell for 18
hours and then replaced the L-cell conditioned medium.
Cells were harvested at different time points ranging from
0 to 24 hours to study the cell cycle by flow cytometry and
the cellular expression of MMP-9 mRNA and protein by
real-time RT-PCR and Western blotting, respectively. This
procedure allowed increasing the percentage of cells in
the S phase from 5 to 10% up to 22%, at most. We then
examined whether increases in the number of cells un-
dergoing cell division were related to increases in MMP-9
expression. We found that the content of MMP-9 protein
was positively correlated with the percentage of cells in
the S phase (linear regression analysis, P  0.001) (Fig-
ure 10A). A similar positive relationship was found for
Figure 7. MPP inhibitors reduce cell growth but only promote cell death at high doses after a 3-day exposure. Cells were exposed to the MMP inhibitors from day 0
to day 3, and then cell growth was assessed with the MTT assay. The MTT value was compared with the basal MTT at time 0. * and #, Comparison versus basal MTT
at time 0 and control MTT at day 3, respectively. After 3 days in culture, MTT values increased in the controls by approximately 75% above basal (P  0.001). A: From
the concentration of 15 mol/L, inhibitor A reduces the 3-day MTT value in relation to the control (0 mol/L inhibitor; #). Increasing concentrations of inhibitor A
progressively reduce the 3-day increase in relation to basal MTT (*). No increase above basal MTT is seen at 20 mol/L, and a reduction below basal is seen from the
concentration of 25 mol/L. B: From the concentration of 1 mol/L, inhibitor B reduces the 3-day MTT value in relation to the control (0 mol/L inhibitor; #). Increasing
concentrations of inhibitor B progressively reduce the 3-day increase in relation to basal MTT (*). No increase above basal MTT is seen at 20 mol/L, and a reduction
below basal is seen from the concentration of 25 mol/L. Values in A and B are expressed as percentage of increase or reduction in relation to basal MTT at time 0 and
are the mean  SEM of n  6 to 18 values per group obtained in two to three independent experiments. C: The mean  SEM percentage of dead and living cells in
relation to total cell number in the culture is not altered by 3-day exposure to MMP inhibitors (n  8 values per group obtained in two independent experiments). D:
In agreement with results of the MTT assay, the trypan blue dye exclusion assay shows that the absolute number of live cells per well (in a 12-well plate) is reduced (P
0.001) after exposure to either 20 mol/L inhibitor A or 15 mol/L inhibitor B. Results were analyzed with one-way analysis of variance followed by Dunnett’s multiple
comparison test to evaluate the effects of treatments against the control. E: SH-SY5Y neuroblastoma cells were transfected with either siRNA against MMP-9 (siRNA-MMP9)
or with nsRNA. After 4 days, cell number was assessed with the MTT assay, and values are expressed as a percentage of nsRNA as the control. Statistical analysis with
Student’s t-test showed a significant reduction in cell growth after silencing of MMP-9 (P  0.001).
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MMP-9 mRNA and numbers of dividing cells (linear re-
gression analysis, P  0.001) (Figure 10B).
To determine whether there was a causal relationship
between MMP-9 expression and cell division, we si-
lenced MMP-9 by transfection with small interfering RNA
(MMP9-siRNA). Controls included cells transfected with a
control nonsilencing RNA sequence (ns-siRNA) and cells
subjected to the transfection process but untreated
(mock). Treatment with siRNA against MMP-9 reduced
the expression of MMP-9 mRNA by approximately 80%
(not shown), and it also reduced MMP-9 protein expres-
sion (Figure 10, C and D). After MMP-9 silencing, the
growth of macrophages from L0 to L4 was significantly
reduced by approximately 70% compared with that in
controls (Figure 10E). We verified that these treatments
did not induce cell death by measuring lactate dehydro-
genase released to the medium (not shown). Finally, we
examined the effect of either the broad-spectrum MMP
inhibitor GM6001 or EDTA in gel zymography. Incubation
of the zymography gels after electrophoresis with either
EDTA or the MMP inhibitor fully prevented the activity of
MMP-9 and MMP-2 (Figure 10F). Taken altogether, these
results show that expression of intracellular MMP-9 in-
creases in dividing macrophages and that MMP-9 par-
ticipates in the process of macrophage cell growth, thus
suggesting that intracellular MMP-9 may be involved in
cell division.
Treatment with Recombinant MMP-9
To investigate whether exogenous MMP-9 might be in-
volved in the above effects, we incubated macrophages
and SK-N-BE-2C neuroblastoma cells with rMMP-9 (50 or
100 ng/ml) after withdrawal of gelatinases from the se-
rum. MMP-9 was successfully removed by incubating the
serum with gelatin-Sepharose beads (Supplemental Fig-
ure 4A, see http://ajp.amjpathol.org). Cells were exposed
to medium containing either normal serum or serum with-
out gelatinases, the latter in the presence or absence of
added rMMP-9. On the next day, cell growth under the
different conditions was examined and compared. Exog-
Figure 8. TGF- enhances cell growth in an
MMP-dependent manner. A: Microscopic phase-
contrast images of SH-SY5Y cells after 6 days in
culture under control conditions. B: Microscopic
phase-contrast images after exposure to 10
ng/ml TGF-, a ligand of EGFR. Scale bar  50
m. MTT assay (expressed as a percentage of
control) (C) and total cell counts per well
(trypan blue exclusion assay) (D) show that
TGF- increases cell growth. E: 4,5-Dianilinoph-
thalimide (DAPH), an inhibitor of the tyrosine
kinase activity of the EGFR, inhibits TGF--in-
duced cell growth, showing that the effect of
TGF- is mediated through EGFR. F and G: MTT
assay after exposure to various concentrations of
MMP inhibitor A (F) and inhibitor B (G) in the
presence of TGF-. TGF--treated cells are sen-
sitive to the effect of MMP inhibitors as they
reduce cell growth. H: Western blot analysis of
cell protein extracts shows a 94-kDa band of
MMP-9 corresponding to the proform, together
with a faint band at lower molecular mass (ap-
proximately 88 kDa). The intensity of this latter
band is enhanced by the presence of TGF- (10
ng/ml), whereas the intensity of the proform
band tends to decrease with this treatment. I:
Zymographic analysis of cellular extracts (see
Materials and Methods) shows that MMP-9 ac-
tivity is enhanced in the presence of TGF-. std,
molecular mass standards. Comparison against
control: *P  0.05; **P  0.001; ***P  0.0001.
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enous rMMP-9 did not increase cell growth in macro-
phages or in neuroblastoma cells (Supplemental Figure
4, B and C, see http://ajp.amjpathol.org).
Discussion
The results of this study support the fact that MMPs play
some function during cell division in neuroblastoma cells
and in primary cultures of macrophages. Stronger gela-
tinase activity and MMP-9 immunoreactivity were de-
tected in cells undergoing mitosis than in resting cells.
This positive reaction was distributed around the chro-
mosomes in a dynamic and well orchestrated fashion at
the different mitotic stages. In addition, MMP inhibitors
disturbed the cell cycle, preventing cells from entering
the S/G2 phase of cell division, and subsequently these
inhibitors reduced cell culture growth and so did silenc-
ing of MMP-9 expression. In addition, stimulation of cell
proliferation with a growth factor, TGF-, was associated
with intracellular MMP activation. The present results
suggest that this MMP might participate in several
steps of cell division in a highly controlled manner,
because of the precise and dynamic intracellular dis-
tribution of MMP-9 immunoreactivity during mitosis.
Therefore, we hypothesize that MMPs might be in-
volved in certain mitotic steps, such as rearrangement
of the cellular matrix, breaking down the nuclear enve-
lope, and/or chromatid segmentation.
Previous studies showed that MMPs may play a role in
intracellular functions. Indeed, MMP-1 is strongly associ-
ated with mitochondria and nuclei, and it accumulates
within the cells during the mitotic phase of the cell cy-
cle.27 Membrane type 1 MMP has been shown to be
trafficked along the tubulin cytoskeleton, to have an in-
tracellular cleavage function, and to cause chromatin
instability.20 Intracellular MMP-2 has been associated
with injury after acute myocardial ischemia/reperfusion,28
and tissue inhibitor of MMP-2 exerts an antimitotic ac-
tion.29 In addition, the presence of several MMPs in the
cell nucleus under pathological conditions has been re-
ported. For instance, atypical localization of membrane
type 1-matrix metalloproteinase in the nucleus is associated
with aggressive features of hepatocellular carcinoma.30
MMP-3 is found in the nucleus and nuclear MMP-3 in-
duced apoptosis via its catalytic activity.31 In addition,
MMP-2 is present in the nucleus of cardiac myocytes and
is capable of cleaving poly(ADP-ribose) polymerase in
vitro.21
In the present study, we report increased MMP-9 im-
munoreactivity in dividing cells, with the highest activity at
the early phases of mitosis. As cell division progressed
and the mitotic spindle was formed, it became apparent
that MMP-9 immunoreactivity was located surrounding
the microtubules. As in the prometaphase, the nuclear
membrane disintegrates32 and the possibility that MMP-9
activity might contribute to nuclear membrane break-
down and/or nuclear matrix reorganization deserves fur-
ther exploration. The structure located between the inner
nuclear membrane and the peripheral chromatin is called
nuclear lamina, which, besides maintaining nuclear ar-
chitecture, is an important cell cycle regulator.33 It is
composed of lamins, the nucleolus, and nuclear matrix
proteins arranged in a fibrillogranular network.34 The nu-
clear lamina interacts with the chromatin,35,36 and it is
disassembled during mitosis.37 Of interest, the nuclear
matrix structure is substantially altered by malignancy.38
During the progression from metaphase to anaphase,
when spindle length increases, MMP-9 immunoreactivity
appeared between the two chromatids as they progres-
sively separated from each other toward the opposite
poles of the mitotic spindle. This location indicates that
MMP activity might participate in cellular matrix rear-
rangement to facilitate separation of the sister chroma-
tids, which is essential to allow precise chromosome
segregation.39 However, the mechanism that controls
this process is not yet fully understood, and certain pro-
teases that participate in sister chromatid separation re-
main unidentified. In addition, identification of targets of
Figure 9. Immunocytochemistry and in situ zymography show that dividing
macrophages have a higher content/activity of MMP-9 than resting cells.
Results of immunocytochemistry are shown in A–F and in situ zymography
is shown in G and H. Images were obtained with the fluorescence micro-
scope. A: Immunocytochemistry for MMP-9 (antibody ab76003 from Abcam)
(green) in primary cultures of macrophages shows higher expression in
certain cells (arrows) compared with others (arrowheads). B: DNA
Hoechst staining (blue) corresponding to the image in A. C: Merged MMP-9
(green) and Hoechst (blue) staining shows that cells with higher MMP-9
expression are dividing cells (arrows). D: -Tubulin (red) staining of the
same images shown in A–C. E: Merged -tubulin (red) and MMP-9 (green)
staining. F: Merged -tubulin, MMP-9, and Hoechst staining of the previous
images. G: In situ zymography showing higher gelatinase activity (green) in
dividing cells (arrows) than in resting cells (arrowheads). H: A broad-
spectrum MMP inhibitor prevents gelatinase activity in the macrophages.
Hoechst staining is shown in blue. Arrows point to dividing cells with high
MMP-9 immunoreactivity, whereas arrowheads point to cells with compar-
atively lower intensity of MMP-9 immunostaining. Scale bars: 50 m (A–F);
20 m (G and H).
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intracellular MMP-9 during cell division would help in
understanding the role of this protease in this process
and whether alterations of its action might be involved in
cell cycle misregulation in tumor cells.
Our study provides evidence for increased expression
of MMP-9 in dividing cells. However, this effect was not
restricted to tumor cells, such as human neuroblastoma
cells, because it was also observed in primary cultures of
rat bone marrow-derived macrophages. Previous studies
showed that angiogenesis and tumor progression were
attenuated in MMP-9-deficient mice.40 However, trans-
plantation of bone marrow-derived CD45-positive leuko-
cytes expressing MMP-9 was sufficient to restore the
tumor phenotype in MMP-9 knockout mice, showing the
importance of the MMP-9 secreted by macrophages in
tumor progression.40 Here, treatment with TGF-, a mito-
genic growth factor acting at the EGFR,17,18,41 increased
cell growth and proliferation though an EGFR-dependent
signaling pathway and caused MMP-9 activation, in
agreement with previous results showing that EGFR ac-
tivates MMP-9.12–15 In contrast, MMP-9 inhibitors reduce
tumor cell growth.5,6,42 TGF--induced cell growth was
also sensitive to the action of MMP-9 inhibitors, thus
suggesting that MMP-9 activation was involved in this
process. In addition, MMP inhibitors and genetic MMP-9
deficiency reduce angiogenesis, and tumor number and
growth during carcinogenesis of pancreatic islets.43 In
our study, we did not find evidence that the reported
effects were attributable to exogenous MMP-9. Further
studies are needed to better understand how intracellular
MMP-9 might be involved in cell division and whether it
might have some influence on tumor growth.
The present findings are based on the use of several
monoclonal antibodies against MMP-9, examination of
gelatinase activity by zymography (in situ and gel), and
the use of MMP inhibitors. These tools have some limita-
tions because the drug inhibitors not only inhibit MMP-9
but gelatinolytic activity might also be due to various
proteases, and we cannot completely exclude the possi-
bility that the monoclonal antibodies might recognize
MMP-9-like proteins. For this reason we silenced the
expression of MMP-9. Preventing MMP-9 expression re-
duced the rate of cell growth, thus suggesting that
MMP-9 was involved in this process.
Taken altogether, the present results support the par-
ticipation of intracellular MMP-9 in certain steps of cell
division in the human neuroblastoma cells and in primary
cultures of rat macrophages.
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